Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-14-0363 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-14-0363 C4160843!4160843 !24919570     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24919570 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Cancer+Res 2014 ; 20 (17 ): 4673-88 Nephropedia Template TP {{tp|p=24919570 |t=2014. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN |pdf=|usr=}}{{24919570 }} gab.com Text To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24919570 #FOAvip PURPOSE: Tumor metastasis is the leading cause of death in patients with cancer. However, the mechanisms that underlie metastatic progression remain unclear. We examined TMEM16A (ANO1) expression as a key factor shifting tumors between growth and metastasis. EXPERIMENTAL DESIGN: We evaluated 26 pairs of primary and metastatic lymph node (LN) tissue from patients with squamous cell carcinoma of the head and neck (SCCHN) for differential expression of TMEM16A. In addition, we identified mechanisms by which TMEM16A expression influences tumor cell motility via proteomic screens of cell lines and in vivo mouse studies of metastasis. RESULTS: Compared with primary tumors, TMEM16A expression decreases in metastatic LNs of patients with SCCHN. Stable reduction of TMEM16A expression enhances cell motility and increases metastases while decreasing tumor proliferation in an orthotopic mouse model. Evaluation of human tumor tissues suggests an epigenetic mechanism for decreasing TMEM16A expression through promoter methylation that correlated with a transition between an epithelial and a mesenchymal phenotype. These effects of TMEM16A expression on tumor cell size and epithelial-to-mesenchymal transition (EMT) required the amino acid residue serine 970 (S970); however, mutation of S970 to alanine does not disrupt the proliferative advantages of TMEM16A overexpression. Furthermore, S970 mediates the association of TMEM16A with Radixin, an actin-scaffolding protein implicated in EMT. CONCLUSIONS: Together, our results identify TMEM16A, an eight transmembrane domain Ca2+-activated Cl- channel, as a primary driver of the "Grow" or "Go" model for cancer progression, in which TMEM16A expression acts to balance tumor proliferation and metastasis via its promoter methylation. Twit Text FOAVip To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24919570 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24919570 #FOAvip English Wikipedia <ref>{{Cite pmid|24919570 }}</ref> To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN #MMPMID24919570 Shiwarski DJ ; Shao C ; Bill A ; Kim J ; Xiao D ; Bertrand CA ; Seethala RS ; Sano D ; Myers JN ; Ha P ; Grandis J ; Gaither LA ; Puthenveedu MA ; Duvvuri U Clin Cancer Res 2014[Sep]; 20 (17 ): 4673-88 PMID24919570 show ga PURPOSE: Tumor metastasis is the leading cause of death in patients with cancer. However, the mechanisms that underlie metastatic progression remain unclear. We examined TMEM16A (ANO1) expression as a key factor shifting tumors between growth and metastasis. EXPERIMENTAL DESIGN: We evaluated 26 pairs of primary and metastatic lymph node (LN) tissue from patients with squamous cell carcinoma of the head and neck (SCCHN) for differential expression of TMEM16A. In addition, we identified mechanisms by which TMEM16A expression influences tumor cell motility via proteomic screens of cell lines and in vivo mouse studies of metastasis. RESULTS: Compared with primary tumors, TMEM16A expression decreases in metastatic LNs of patients with SCCHN. Stable reduction of TMEM16A expression enhances cell motility and increases metastases while decreasing tumor proliferation in an orthotopic mouse model. Evaluation of human tumor tissues suggests an epigenetic mechanism for decreasing TMEM16A expression through promoter methylation that correlated with a transition between an epithelial and a mesenchymal phenotype. These effects of TMEM16A expression on tumor cell size and epithelial-to-mesenchymal transition (EMT) required the amino acid residue serine 970 (S970); however, mutation of S970 to alanine does not disrupt the proliferative advantages of TMEM16A overexpression. Furthermore, S970 mediates the association of TMEM16A with Radixin, an actin-scaffolding protein implicated in EMT. CONCLUSIONS: Together, our results identify TMEM16A, an eight transmembrane domain Ca2+-activated Cl- channel, as a primary driver of the "Grow" or "Go" model for cancer progression, in which TMEM16A expression acts to balance tumor proliferation and metastasis via its promoter methylation. |Animals [MESH] |Anoctamin-1 [MESH] |Carcinogenesis/*genetics [MESH] |Carcinoma, Squamous Cell/*genetics/pathology [MESH] |Cell Line, Tumor [MESH] |Cell Movement/genetics [MESH] |Cell Proliferation/*genetics [MESH] |Chloride Channels/*biosynthesis/genetics [MESH] |Cytoskeletal Proteins/genetics [MESH] |DNA Methylation/genetics [MESH] |Epithelial-Mesenchymal Transition/*genetics [MESH] |Gene Expression Regulation, Neoplastic [MESH] |Head and Neck Neoplasms/*genetics/pathology [MESH] |Humans [MESH] |Lymphatic Metastasis/genetics [MESH] |Membrane Proteins/genetics [MESH] |Mice [MESH] |Neoplasm Proteins/*biosynthesis/genetics [MESH] |Squamous Cell Carcinoma of Head and Neck [MESH]To "grow" or "go": TMEM16A expression as a switch between tumor growth(epmc).pdf DeepDyve Pubget Overpricing